I have already suggested that SARS-CoV-2 is able to induce shedding of the zinc-carboxypeptidase ACE2 by activating the zinc-metalloprotease ADAM17, finally leading to systemic upregulation of ACE2 activity in COVID-19 patients [3]. This evidence concerns the gene ADAM17 and COVID-19.